眼部非侵入性蛋白质输送的一个有希望的策略:在治疗角膜新血管化的情况下
Bangxun Mao1, Bojiao Tang2, Songping Yu1
1Department of Ophthalmology, The Fifth Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Lishui, 323000, China.
Acta biomaterialia
|February 8, 2025
概括
一种名为CmA@Beva的新型纳米药物提供了用于角膜新血管化 (CNV) 的非侵入性眼滴治疗方法. 这种先进的输送系统增强了蛋白质药物保留和透,改善了视力障碍的治疗结果.
科学领域:
- 眼科医生和纳米医学
- 生物材料和药物输送
背景情况:
- 角膜新血管化 (CNV) 是视力丧失的主要原因,目前的治疗方法,如葡萄糖皮质类药物是无效的,并具有副作用.
- 贝瓦西祖马布 (Beva) 对心肺结核病毒有前途,但由于眼球透率差,其下结膜注射限制了疗效,并可能导致感染.
- 通过眼障碍物有效的非侵入性输送蛋白质药物仍然是治疗前段眼部疾病的重大挑战.
研究的目的:
- 开发和评估一种新型纳米药物,CmA@Beva,用于增强贝瓦西祖马布 (Beva) 的眼部输送.
- 调查CmA@Beva眼滴作为治疗角膜新血管化的亚结节注射的非侵入性替代品的潜力.
主要方法:
- 一个新 (Cysteine-Histidine-Arginine) 3与Beva在Zn2+的存在下联合组装,形成CmA@Beva纳米药.
- 优化CmA形成和Beva封装,然后评估pH响应释放和Beva保护.
- 在体外和体内研究评估CmA@Beva的生物相容性,眼睛保留,角膜屏障透和治疗疗效.
主要成果:
- CmA@Beva表现出良好的生物相容性,并在眼前部分显著改善了Beva的保留时间.
- 纳米医学有效地绕过角膜生物障碍,通过打开紧密的结口和利用内细胞结合-溶酶体逃生通路.
- 与传统的副结膜注射相比,CmA@Beva眼药在老鼠的中枢结膜病毒中取得了更好的治疗效果.
结论:
- CmA@Beva纳米医学提供了一种有效的非侵入性策略,可以将像Beva这样的蛋白质药物输送到眼睛前部.
- 这种方法克服了传统治疗的局限性,为角膜新血管化提供了更高的疗效和患者遵守性.
- 开发的纳米医学有望通过改善药物输送来治疗CNV和其他前段眼部疾病.
相关概念视频
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...